Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427289 | 0.88 | HTR6 (0.52) | KDM4EHPGDHSD17B10HTR6POLB | |
| SCHEMBL3425156 | 0.84 | KDM4E (0.42) | KDM4EHSD17B10HTR6POLBALDH1A1 | |
| SCHEMBL3426573 | 0.84 | HTR6 (0.53) | HTR6ALDH1A1HTT | |
| SCHEMBL3428016 | 0.78 | RAB9A (0.51) | KDM4EHTR6ALDH1A1MEN1KMT2A | |
| SCHEMBL3426667 | 0.78 | HTR6 (0.65) | HTR6ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL3426369 | 0.77 | HTR6 (0.64) | HTR6ALDH1A1HTT | |
| SCHEMBL3426990 | 0.77 | HTR6 (0.52) | KDM4EHTR6ALDH1A1 | |
| SCHEMBL3426339 | 0.76 | HTR6 (0.49) | HTR6ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL3427636 | 0.75 | HTR6 (0.48) | HTR6ALDH1A1HTT | |
| SCHEMBL3426322 | 0.75 | POLB (0.45) | KDM4EHTR6POLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | claimed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | claimed |
| EP-1581538-B1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-02-28 | — | — | EP | claimed |
| EP-1581538-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | claimed |
| WO-2004055026-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-07-01 | — | — | WO | claimed |
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
| EP-1581538-B1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-02-28 | — | — | EP | disclosed |
| EP-1581538-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055026-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | KDM4E 3790/4885HPGD 3840/4885HSD17B10 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.